Desogestrel
drugOn this page
Also known as AizeaCerazetteCerelleDesogestrel component of bekyreeDesogestrel component of cyclessaDesogestrel component of desogenDesogestrel component of enskyceDesogestrel component of isibloomDesogestrel component of karivaDesogestrel component of mircetteDesogestrel component of ortho-ceptDesogestrel component of pimtreaDesogestrel component of velivetDesogestrel component of vioreleDesogestrel component of volneaDesomonoFeanollaMircetteNacrez
Summary
Desogestrel (CHEMBL1533) is an approved small-molecule contraceptive drug (ATC G03AC09); indicated across 5 conditions including polycystic ovary syndrome and amenorrhea.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: G03AC09
- Indications: 5 conditions
- Clinical trials: 21
- Chemistry: 310.5 Da · C22H30O
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1533 |
| Name | Desogestrel |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 40973 |
| ChEBI | CHEBI:4453 |
| ATC | G03AC09 |
| Molecular formula | C22H30O |
| Molecular weight | 310.5 |
| InChIKey | RPLCPCMSCLEKRS-BPIQYHPVSA-N |
SMILES: CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34
IUPAC name: (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
Pharmacological roles (ChEBI): contraceptive drug, progestin, synthetic oral contraceptive.
Also known as: Aizea, Cerazette, Cerelle, Desogestrel, Desogestrel component of bekyree, Desogestrel component of cyclessa, Desogestrel component of desogen, Desogestrel component of enskyce, Desogestrel component of isibloom, Desogestrel component of kariva, Desogestrel component of mircette, Desogestrel component of ortho-cept
Patent coverage: 2,612 distinct patent families (9,566 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: Androgen receptor, Glucocorticoid receptor, D(1A) dopamine receptor, Estrogen receptor, Progesterone receptor, Muscarinic acetylcholine receptor M2, Prostaglandin G/H synthase 1, Sodium-dependent noradrenaline transporter, Type-1 angiotensin II receptor, Sodium-dependent serotonin transporter.
Bioactivity
ChEMBL activities: 15 potent at pChembl ≥ 5 of 25 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| PGR | 8.52 | AC50 | 3 | nM | CHEMBL_ACT_25204359 |
| PGR | 8.52 | AC50 | 3 | nM | CHEMBL_ACT_25222976 |
| P15207 | 6.96 | AC50 | 110 | nM | CHEMBL_ACT_25232823 |
| AR | 6.92 | AC50 | 120 | nM | CHEMBL_ACT_25203426 |
| NR3C1 | 6.85 | AC50 | 140 | nM | CHEMBL_ACT_25175774 |
| SHBG | 6.6 | Kd | 251.2 | nM | CHEMBL_ACT_2155691 |
| ESR1 | 6.25 | AC50 | 560 | nM | CHEMBL_ACT_25138926 |
| CHRM2 | 5.74 | AC50 | 1830 | nM | CHEMBL_ACT_25195804 |
| SLC6A2 | 5.72 | AC50 | 1890 | nM | CHEMBL_ACT_25146068 |
| NR1I2 | 5.62 | AC50 | 2400 | nM | CHEMBL_ACT_25188121 |
| ESR1 | 5.54 | AC50 | 2900 | nM | CHEMBL_ACT_25167244 |
| SLC6A2 | 5.29 | AC50 | 5100 | nM | CHEMBL_ACT_25144920 |
| DRD3 | 5.29 | AC50 | 5100 | nM | CHEMBL_ACT_25194590 |
| ADORA3 | 5.22 | AC50 | 6000 | nM | CHEMBL_ACT_25134129 |
| SLC6A4 | 5 | AC50 | 10000 | nM | CHEMBL_ACT_25150256 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| polycystic ovary syndrome | 3 | MONDO:0008487 | EFO:0000660 |
| amenorrhea | 3 | MONDO:0001836 | EFO:0010269 |
| infertility disorder | 3 | MONDO:0005047 | EFO:0000545 |
| central sleep apnea syndrome | 2 | MONDO:0004731 | MONDO:0800026 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 21.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 5 |
| Not specified | 5 |
| PHASE1 | 4 |
| PHASE2 | 3 |
| PHASE3 | 2 |
| PHASE2/PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06334315 | PHASE4 | RECRUITING | Oral Contraceptive Pill (OCP) Pharmacogenomics |
| NCT01738724 | PHASE4 | TERMINATED | Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin |
| NCT02757287 | PHASE4 | WITHDRAWN | Desogestrel (DSG) and Corifollitropin(FSH-CTP) Alfa for Ovarian Stimulation in Donors |
| NCT04728659 | PHASE4 | UNKNOWN | Desogestrel Versus GnRH Antagonist in IVF/ICSI |
| NCT05002738 | PHASE4 | COMPLETED | Desogestrel-containing COCP Pharmacokinetic Validation Study |
| NCT00946192 | PHASE3 | COMPLETED | Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes |
| NCT01243697 | PHASE2/PHASE3 | COMPLETED | Assessment of Desogestrel in Ondine Syndrome |
| NCT02103764 | PHASE3 | UNKNOWN | Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB |
| NCT04941833 | PHASE2/PHASE3 | COMPLETED | Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo |
| NCT00563472 | PHASE2 | COMPLETED | Feasibility Study Into the Contraceptive Effect of Estetrol |
| NCT01388491 | PHASE2 | COMPLETED | A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women |
| NCT01500473 | PHASE2 | TERMINATED | Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome |
| NCT01291004 | PHASE1 | COMPLETED | A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives |
| NCT03353857 | PHASE1 | COMPLETED | Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam |
| NCT04422028 | PHASE1 | COMPLETED | Bioavailability of Desogestrel 0.075 mg Tablets With Regards to Reference Product |
| NCT07269327 | PHASE1 | COMPLETED | An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin |
| NCT00204438 | Not specified | COMPLETED | Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle |
| NCT01005056 | Not specified | COMPLETED | Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083) |
| NCT01559480 | Not specified | COMPLETED | Postoperative Desogestrel for Endometriosis Related Pain |
| NCT03398811 | Not specified | COMPLETED | Abnormal Uterine Bleeding and Progestin-only Contraceptives |
| NCT05174195 | Not specified | TERMINATED | Does Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year? |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: polycystic ovary syndrome, amenorrhea, infertility disorder